Taysha Gene Therapies’ (TSHA) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note issued to investors on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has a $7.00 price objective on the stock.

A number of other equities analysts have also weighed in on TSHA. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Canaccord Genuity Group reduced their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Trading Down 9.3 %

Shares of TSHA stock opened at $2.06 on Tuesday. The firm has a market capitalization of $422.18 million, a P/E ratio of 3.27 and a beta of 0.44. Taysha Gene Therapies has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The stock’s fifty day moving average is $1.98 and its two-hundred day moving average is $2.38. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.22 and a current ratio of 5.22.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently bought and sold shares of the company. Barclays PLC grew its position in Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after acquiring an additional 193,046 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Taysha Gene Therapies in the third quarter valued at approximately $931,000. State Street Corp raised its holdings in shares of Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after purchasing an additional 150,647 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Taysha Gene Therapies by 81.9% during the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after purchasing an additional 34,243 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Taysha Gene Therapies by 7.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after purchasing an additional 33,123 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.